Abbott’s FreeStyle Libre System, which was approved by the U.S. Food and Drug Administration in September and launched in U.S. pharmacies in November, has met the criteria for therapeutic continuous glucose monitoring used for coverage by the U.S. Centers for Medicare and Medicaid Service, Abbott said.
Although I do not yet see a confirmation statement directly from Medicare. Which of course would be interesting. Particularly as it was the Medicare “fine print” in regards to the Dexcom coverage which continues to cause significant displeasure.
Hmmm… Wondering if Abbott is getting tricky with wording.
"… met the criteria …"
Actually is not QUITE the same as Medicare PROVIDING coverage.
With that point, I certainly would not be arguing. I understand reality.
However, without a corresponding statement/release from Medicare than this sounds like Abbott just playing games and basically rehashing the FDA approval. This would accomplish two items:
Get people confused
Play with stock prices
Neither one is playing fair or above board. Maybe I am wrong and just jumping to conclusions. If Medicare immediately comes out with a confirmation statement then great. Abbott is helping patients and I am just a paranoid freak.
If not then Abbott should be investigated for false and misleading claims by Medicare and the SEC.
I actually just think this is an intermediate step that was achieved in their goal to get Medicare approval. It is certainly not the approval, but I think it means they weren’t rejected after the first review/gateway.
ha !!! Good Luck on that. They would need to HAVE a cgm for that first. (ie - their device is FLASH not CONTINUOUS although they may try to insinuate and imply to the contrary but they will not outright state it.)
That is entirely plausible. I fully expect the Dexcom stock to recover from its dip today. DXCM (stock price) was down about 12% at its lowest today as compared to yesterday’s closing price. As of right now, DXCM has already recovered about 30% of its loss. If this was a premature announcement than I am certain DXCM stock will recover quite rapidly. Long term, I think this is a non-issue regardless.
The entire market for continuous (or flash) glucose monitors is large enough for multiple players. Competition is helpful and benefits all patients. Not to mention, choice is good and for whatever reason if somebody wants to pick the Abbott system over the Dexcom system then it is great to be given that choice.
Competition is good for patients no doubt, but companies that are first to market sometime have difficulties transitioning to a market with competition. i.e. KCI in the wound vacuum market. Not saying Dexcom is going to have this difficulty, but being second to market has some advantages.
In the last Dexcom quarter conference call they mentioned the competition with Libre quite a bit. One of their points was that for someone who uses the G5 with a phone and who restarts their sensors, the cost per day of the Dex really isn’t any higher than the cost of the Libre. They were talking specifically about Europe, where they don’t sell a Dex receiver to a new patient who intends to use the phone.
i am glad that i found this thread. i have tried the dexcom twice for periods of 1 year, and then again for about 3 months. the system NEVER worked for me and i was very very frustrated and disappointed.
i am glad that i have another option. and i dont own stock in either company, just my overall well-being.